ABAlison Tytell Brenner

Alison Tytell Brenner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alison Tytell Brenner has a total of 208 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expanding access to colorectal cancer screening through community pharmacies: study protocol for the PharmFIT™ randomized controlled trial

    by Morgan Glascock, Mary Wangen, Renee M. Ferrari, Meghan C. O&Apos;Leary, Jessie Schwartz, Michelle Ndugulile, Joseph M. Unger, Catherine Fedorenko, Li Li, Macary Weck Marcinkiak, et al.

    Background. Colorectal cancer (CRC) is a leading cause of cancer death. Fecal immunochemical test (FIT) screening remains underused, particularly in underserved communities. Community pharmacies are highly accessible and increasingly deliver preventive care, yet pharmacy-based CRC screening has not been tested in a large pragmatic randomized trial with concurrent implementation and economic evaluation. This protocol describes a pragmatic trial testing a pharmacy-based CRC screening intervention using FIT, called PharmFIT™, which integrates community pharmacies into CRC screening pathways for primary care patients due for screening.Methods. PharmFIT™ is a two-arm, pragmatic, hybrid type 1 effectiveness–implementation trial in two geographically disparate states (Washington and North Carolina). Adults aged 45–75 years, due for CRC screening, are randomized (n=1,200) to PharmFIT™ or usual care. In the intervention arm, clinics recommend CRC screening and refer patients to partner pharmacies, and pharmacists counsel patients, dispense FIT kits, and support kit return and follow-up. The primary outcome is completion of any United States Preventive Services Task Force–recommended CRC screening test within 6 months. Secondary outcomes include reach, timeliness of FIT completion and follow-up colonoscopy, and screening differences across patient subgroups. Implementation outcomes (acceptability, appropriateness, feasibility, fidelity, cost) are assessed using mixed methods, and economic analyses estimate intervention implementation costs, incremental cost per additional patient screened, and budget impact conducted from pharmacy and societal perspectives.Conclusions. PharmFIT™ will provide effectiveness, implementation, and cost evidence for pharmacy-based CRC screening, informing the scalability of pharmacist-led cancer prevention within primary care.

  • Open Access

    Designing a colorectal cancer screening program for community pharmacies: Findings from a national survey of pharmacists

    by Parth D. Shah, Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Renée Ferrari, Macary W. Marciniak, Stephanie B. Wheeler, Alison T. Brenner

  • Open Access

    What makes patient navigation work? Identifying functions and forms and conducting causal loop diagramming to specify components of a successful colorectal cancer patient navigation program

    by Renée M. Ferrari, Connor M. Randolph, Meghan C. O’lEary, Kristen Hassmiller Lich, Alexis A. Moore, Jennifer Leeman, Alison T. Brenner, Stephanie B. Wheeler, Seth D. Crockett, Daniel S. Reuland

    We implemented a centralized colorectal cancer (CRC) screening program with navigation to follow-up colonoscopy for community health center (CHC) patients


  • Open Access

    Design and Interim Recruitment Outcomes of a Multi-Modal, Multi-Level Patient Navigation Intervention for Lung Cancer Screening in the Southeast U.S.

    by Marvella E. Ford, Louise Henderson, Alison Brenner, Vanessa B. Sheppard, Stephanie B. Wheeler, Tiffani Collins, Monique Williams, Rosuany Vélez Acevedo, Christopher Lyu, Chyanne Summers, et al.

    Background/Objectives: Lung cancer is the leading cause of cancer death in the United States (U.S.). Virginia, South Carolina, and North Carolina are among the U.S. states with extraordinarily high rates of lung cancer mortality, particularly among Black residents. The current lung cancer screening guidelines, revised in 2021, support screening for younger, non-Medicare age-eligible individuals who smoke. However, their health insurance, if any, may not cover their screening. This lack of access could create more disparities in lung cancer mortality rates. Methods: To address this concern, the Virginia Commonwealth University Massey Comprehensive Cancer Center, the Medical University of South Carolina Hollings Cancer Center, and the University of North Carolina Chapel Hill Lineberger Comprehensive Cancer Center secured a four-year Stand Up To Cancer® (SU2C) grant titled “Southeastern Consortium for Lung Cancer Screening (SC3) Study” with a novel aim to test the effectiveness of a multimodal, multilevel, barrier-focused patient navigation intervention to promote lung cancer screening among Black patients from federally qualified health centers. Results: A total of 170/675 Black participants have been recruited to date. The majority of participants (n = 134; 78.82%) were aged 55–74 years. Most participants were unmarried (n = 100; 58.82%), more than half had a high school education/GED or less (n = 111; 65.29%), most currently smoked (n = 142; 83.53%), and more males than females participated (n = 107; 62.94% male). Their reported lung cancer screening barriers, addressed by the patient navigators, were cost concerns, insurance coverage issues, and recent medical history precluding screening. Conclusions with Relevance to Cancer Health Equity: This SC3 study includes a unique lung cancer screening cohort that is in direct contrast to the predominantly White cohort in the National Lung Screening Trial. The SU2C study has created a novel, community-engaged approach to lung cancer screening navigation that could become the gold standard in high-risk medically underserved populations.


  • Open Access

    Data from It Is a Good Idea, but Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening

    by Alison T. Brenner, Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, Parth D. Shah

    Background:Accessibility, expanding scope of practice, and a rapidly changing policy landscape make US community pharmacies a promising delivery setting for colorectal cancer screening. It is not clear, however, whether community pharmacists are willing to incorporate colorectal cancer screening into their pharmacy practice, what potential drivers of willingness are, and, if unwilling, under what conditions pharmacists would be willing to provide PharmFIT.Methods:From September 2022 to January 2023, we surveyed 578 currently practicing community pharmacists. We assessed willingness to provide a pharmacy-based colorectal cancer screening program (PharmFIT). We used multiple linear regression to identify correlates of perceived implementation complexity and multiple logistic regression to explore overall willingness to implement PharmFIT.Results:Most pharmacists (80%) were willing to implement PharmFIT. The most common reasons for unwillingness were that results needed to be reported to the patients’ primary care providers (52%), that appropriate training in delivering colorectal cancer screening be provided (48%), and that care coordination with primary care providers be clear (46%). Perceived complexity of the intervention decreased as years in practice increased [β = 0.013; 95% confidence interval (CI), 0.01–0.02] and as the level of knowledge about colorectal cancer screening increased (β = 0.085; 95% CI, 0.01–0.16). Respondents’ willingness to implement PharmFIT increased as perceived complexity decreased (OR = 5.68; 95% CI, 3.96–8.15).Conclusions:Most community pharmacists in the United States would be willing to integrate PharmFIT into their current workflows. Training in how to deliver fecal immunochemical testing and preparation for the coordination of test results and follow-up care should be completed prior to implementing PharmFIT.Impact:Community pharmacies are a viable venue for delivering colorectal cancer screening.

  • Open Access

    Supplementary Figure 1 from It Is a Good Idea, but Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening

    by Alison T. Brenner, Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, Parth D. Shah

    Supplementary Figure 1. A flow diagram depicting the composition of the analytic samples for the outcomes of “Willingness to provide PharmFIT” and “Complexity of PharmFIT”.

  • Open Access

    Design and Interim Recruitment Outcomes of a Multi-Modal, Multi-Level Patient Navigation Intervention for Lung Cancer Screening in the Southeast U.S.

    by Marvella E. Ford, Louise Henderson, Alison Brenner, Vanessa B. Sheppard, Stephanie B. Wheeler, Tiffani Collins, Monique Williams, Rosuany Vélez Acevedo, Christopher Lyu, Chyanne Summers, et al.

    Background/Objectives: Lung cancer is the leading cause of cancer death in the United States (U.S.). Virginia, South Carolina, and North Carolina are among the U.S. states with extraordinarily high rates of lung cancer mortality, particularly among Black residents. The current lung cancer screening guidelines, revised in 2021, support screening for younger, non-Medicare age-eligible individuals who smoke. However, their health insurance, if any, may not cover their screening. This lack of access could create more disparities in lung cancer mortality rates. Methods: To address this concern, the Virginia Commonwealth University Massey Comprehensive Cancer Center, the Medical University of South Carolina Hollings Cancer Center, and the University of North Carolina Chapel Hill Lineberger Comprehensive Cancer Center secured a four-year Stand Up To Cancer® (SU2C) grant with a novel aim to test the effectiveness of a multimodal, multilevel, barrier-focused patient navigation intervention to promote lung cancer screening among Black patients from federally qualified health centers. Results: A total of 170/675 Black participants have been recruited to date. The majority of participants (n=134; 78.82%) were aged 55-74 years. Most participants were unmarried (n=100; 58.82%), more than half had a high school education/GED or less (n=111; 65.29%), most currently smoked (n=142; 83.53%), and more males than females participated (n=107; 62.94% male). Their reported lung cancer screening barriers, addressed by the patient navigators, were cost concerns, insurance coverage issues, and recent medical history precluding screening. Conclusions with Relevance to Cancer Health Equity: This SU2C study includes a unique lung cancer screening cohort that is in direct contrast to the predominantly White cohort in the National Lung Screening Trial. The SU2C study has created a novel, community-engaged approach to lung cancer screening navigation that could become the gold standard in high-risk medically underserved populations.

  • It Is a Good Idea, but Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening

    by Alison T. Brenner, Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, Parth D. Shah

    Background: Accessibility, expanding scope of practice, and a rapidly changing policy landscape make US community pharmacies a promising delivery setting for colorectal cancer screening. It is not clear, however, whether community pharmacists are willing to incorporate colorectal cancer screening into their pharmacy practice, what potential drivers of willingness are, and, if unwilling, under what conditions pharmacists would be willing to provide PharmFIT. Methods: From September 2022 to January 2023, we surveyed 578 currently practicing community pharmacists. We assessed willingness to provide a pharmacy-based colorectal cancer screening program (PharmFIT). We used multiple linear regression to identify correlates of perceived implementation complexity and multiple logistic regression to explore overall willingness to implement PharmFIT. Results: Most pharmacists (80%) were willing to implement PharmFIT. The most common reasons for unwillingness were that results needed to be reported to the patients’ primary care providers (52%), that appropriate training in delivering colorectal cancer screening be provided (48%), and that care coordination with primary care providers be clear (46%). Perceived complexity of the intervention decreased as years in practice increased [β = 0.013; 95% confidence interval (CI), 0.01–0.02] and as the level of knowledge about colorectal cancer screening increased (β = 0.085; 95% CI, 0.01–0.16). Respondents’ willingness to implement PharmFIT increased as perceived complexity decreased (OR = 5.68; 95% CI, 3.96–8.15). Conclusions: Most community pharmacists in the United States would be willing to integrate PharmFIT into their current workflows. Training in how to deliver fecal immunochemical testing and preparation for the coordination of test results and follow-up care should be completed prior to implementing PharmFIT. Impact: Community pharmacies are a viable venue for delivering colorectal cancer screening.


  • Open Access

    Colorectal cancer screening knowledge among community pharmacists: A national survey

    by Olufeyisayo O. Odebunmi, Mary Wangen, Austin R. Waters, Renée M. Ferrari, Macary Weck Marciniak, Catherine Rohweder, Stephanie B. Wheeler, Alison T. Brenner, Parth D. Shah


  • Open Access

    Findings From a National Survey of Older US Adults on Patient Willingness to Use Telehealth Services: Cross-Sectional Survey

    by Olufeyisayo O Odebunmi, Tamera D Hughes, Austin R Waters, Benjamin Y Urick, Caroline Herron, Mary Wangen, Catherine Rohweder, Renée M Ferrari, Macary W Marciniak, Stephanie B Wheeler, et al.

    Background: Telehealth (telemedicine and telepharmacy) services increase access to patient services and ensure continuity of care. However, few studies have assessed factors that influence patients’ willingness to use telehealth services, and we sought to investigate this. Objective: This study aims to examine respondents’ (aged between 45 and 75 years) willingness to use telehealth services (telepharmacy and telemedicine) and the correlates of the willingness to use telehealth services. Methods: We administered a cross-sectional national survey of 1045 noninstitutionalized US adults aged between 45 and 75 years in March and April 2021. Multiple logistic regression analyses were used to identify demographic and health service use correlates of self-reported willingness to use telehealth services. Results: Overall willingness to use telemedicine was high (674/1045, 64.5%). Adults aged 55 years and older were less willing to use telemedicine (aged between 55 and 64 years: odds ratio [OR] 0.61, 95% CI 0.42-0.86; aged 65 years or older: OR 0.33, 95% CI 0.22-0.49) than those younger than 55 years. Those with a regular provider (OR 1.01, 95% CI 1-1.02) and long travel times (OR 1.75, 95% CI 1.03-2.98) were more willing to use telemedicine compared to those without a regular provider and had shorter travel times, respectively. Willingness to use telemedicine services increased from 64.5% (674/1045) to 83% (867/1045) if the service was low-cost or insurance-covered, was with their existing health care provider, or was easy-to-use. Overall willingness to use telepharmacy was 76.7% (801/1045). Adults aged older than 55 years were less willing to use telepharmacy (aged between 55 and 64 years: OR 0.57, 95% CI 0.38-0.86; aged 65 years or older: OR 0.24, 95% CI 0.15-0.37) than those younger than 55 years. Those who rated pharmacy service quality higher were more willing to use telepharmacy (OR 1.06, 95% CI 1.03-1.09) than those who did not. Conclusions: Respondents were generally willing to use telehealth (telemedicine and telepharmacy) services, but the likelihood of their being willing to use telehealth decreased as they were older. For those initially unwilling (aged 55 years or older) to use telemedicine services, inexpensive or insurance-covered services were acceptable.